GC Cell Corp
KOSDAQ:144510
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GC Cell Corp
Accounts Receivables
GC Cell Corp
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GC Cell Corp
KOSDAQ:144510
|
Accounts Receivables
₩18.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accounts Receivables
₩2T
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Accounts Receivables
₩123.7B
|
CAGR 3-Years
44%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accounts Receivables
₩80.8m
|
CAGR 3-Years
332%
|
CAGR 5-Years
141%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accounts Receivables
₩37.2B
|
CAGR 3-Years
64%
|
CAGR 5-Years
81%
|
CAGR 10-Years
57%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accounts Receivables
₩59.1B
|
CAGR 3-Years
2 371%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GC Cell Corp
Glance View
GC Cell Corp. engages in the research and development of cell curing agents and in the transport and sale of consignment inspection samples. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2016-06-23. The firm operates its business through four segments. The Specimen Testing Service segment provides sample testing services, clinical trial services, and veterinary testing services. The Cell Therapy segment is engaged in cell culture and technology transfer business. The Cord Blood Storage segment is engaged in the cord blood storage business. The Other Business segment is engaged in bio-logistics business and others.
See Also
What is GC Cell Corp's Accounts Receivables?
Accounts Receivables
18.5B
KRW
Based on the financial report for Dec 31, 2025, GC Cell Corp's Accounts Receivables amounts to 18.5B KRW.
What is GC Cell Corp's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
9%
Over the last year, the Accounts Receivables growth was -5%. The average annual Accounts Receivables growth rates for GC Cell Corp have been -17% over the past three years , 9% over the past five years .
